Research News on Targeted Therapies
-
Heart Problems Caused by Herceptin May Be More Common Than Thought
A small study has found that after 3 months of Herceptin treatment nearly 58% of women had some loss of heart function.
-
Experimental Omnitarg May Help Treat Metastatic, HER2-Positive Disease
Research suggests that adding the experimental medicine Omnitarg to a combination of Herceptin and Taxotere slows the growth of metastatic HER2-positive breast cancer more than Herceptin and Taxotere alone.
-
Adding Avastin Slows Growth of Metastatic, HER2-Positive Disease
A study has found that adding Avastin (chemical name: bevacizumab) to a combination of Herceptin (chemical name: trastuzumab) and Taxotere (chemical name: docetaxel) increased the likelihood of respond...
-
Afinitor Helps Slow Growth of Certain Advanced-Stage Breast Cancers
New information from the BOLERO-2 study shows that women diagnosed with hormone-receptor-positive, HER2-negative advanced-stage or metastatic breast cancer who got Afinitor and Aromasin in combination lived more than twice as long without the cancer growing than women who got only Aromasin.
-
FDA Removes Breast Cancer Indication from Avastin
On Nov. 18, 2011 FDA Commissioner Margaret Hamburg decided to remove the breast cancer indication from Avastin.
-
Experimental Vaccine May Help Treat Some Advanced-Stage Cancers
A very small, very early study suggests that some women diagnosed with advanced-stage breast or ovarian cancer may get some benefit from an experimental vaccine that targets breast and ovarian cancer cells.
-
Treating Early-Stage, HER2-Positive Disease with Herceptin and Chemo Combo with No Anthracycline Reduces Heart Risks
A study has found that Herceptin plus chemotherapy that didn't include an anthracycline after surgery was as effective as Herceptin plus chemotherapy that included an anthracycline for women diagnosed with HER2-positive, early-stage breast cancer.
-
Blue Shield of California Will No Longer Pay for Avastin to Treat Advanced-Stage Breast Cancer
Blue Shield of California has announced it will no longer pay for bevacizumab (Avastin) to treat advanced breast cancer. This is the largest insurer to stop coverage since an FDA panel voted that the drug's breast cancer indication should be removed.
-
Avastin Plus Taxol May Help Treat Metastatic, Triple-Negative Disease
Some women diagnosed with triple-negative metastatic breast cancer benefit from a combination of Avastin and Taxol.
-
Adding Iniparib to Second, Third Chemo Regimen May Help Treat Metastatic, Triple-Negative Disease
A new analysis suggests that women diagnosed with triple-negative metastatic breast cancer that was previously treated benefited from adding iniparib to the second or third chemotherapy regimen.
